Avastin-eluting stent: long-term angiographic and clinical follow up.
The detection of atheromatous lesions in patients with coronary artery disease is related to neovascularisation, since it is associated with the presence of a dense network of vasa vasorum in the vascular wall. The increased density of vasa vasorum causes destabilisation of the atheromatous plaque. The safety and efficacy of a stent coated with bevacizumab, a monoclonal antibody for vascular endothelial growth factor have been established at both the experimental and the clinical level. We present the case of a patient with acute myocardial infarction and significant stenosis in the mid-section of the left anterior descending coronary artery, treated by implantation of a bevacizumab-coated stent. A coronary angiographic examination 2 years later showed patent coronary arteries with a well-preserved angioplasty result in the anterior descending artery. This is the first report of findings beyond six-month follow up of this type of stent and represents the first clinical and angiographic proof of its long-term efficacy.
First Department of Cardiology, Athens Medical School, Athens, Greece. chstefan@med.uoa.gr
Christodoulos
C
Stefanadis
Konstantinos
K
Toutouzas
Elli
E
Stefanadi
Eleftherios
E
Tsiamis
Manolis
M
Vavuranakis
Nicholas
N
Kipshidze
D020533:Angiogenesis Inhibitors; D015906:Angioplasty, Balloon, Coronary; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D017023:Coronary Angiography; D003324:Coronary Artery Disease / Q000000981:diagnostic imaging / Q000628:therapy*; D054855:Drug-Eluting Stents; D016228:Endothelial Growth Factors; D006801:Humans; D008297:Male; D008875:Middle Aged; D014654:Vascular Patency
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D016228:Endothelial Growth Factors; D000068258:Bevacizumab